Preferential PDE4B Inhibition - A Step toward a New Treatment for Idiopathic Pulmonary Fibrosis

Affiliations

Editorial

Rachel C Chambers. N Engl J Med. 2022.

. 2022 Jun 9;386(23):2235-2236.

doi: 10.1056/NEJMe2205411.

¹ From the Centre for Inflammation and Tissue Repair (UCL Respiratory), Division of Medicine, University College London, London.

No abstract available

Comment in

Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis.
Raghu G. Raghu G. N Engl J Med. 2022 Aug 25;387(8):761. doi: 10.1056/NEJMc2209529. N Engl J Med. 2022. PMID: 36001723 No abstract available.
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis.
Spagnolo P, Bonella F. Spagnolo P, et al. N Engl J Med. 2022 Aug 25;387(8):761-762. doi: 10.1056/NEJMc2209529. N Engl J Med. 2022. PMID: 36001724 No abstract available.

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.
Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM; 1305-0013 Trial Investigators. Richeldi L, et al. N Engl J Med. 2022 Jun 9;386(23):2178-2187. doi: 10.1056/NEJMoa2201737. Epub 2022 May 15. N Engl J Med. 2022. PMID: 35569036 Clinical Trial.